Merus Balance Sheet Health
Financial Health criteria checks 6/6
Merus has a total shareholder equity of $356.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $455.5M and $99.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$354.38m |
| Equity | US$356.34m |
| Total liabilities | US$99.15m |
| Total assets | US$455.49m |
Recent financial health updates
We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19
Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Recent updates
Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Jun 04Merus EPS misses by $0.10, misses on revenue
May 06Is Merus N.V. (NASDAQ:MRUS) Popular Amongst Institutions?
Mar 08Financial Position Analysis
Short Term Liabilities: MRUS's short term assets ($368.8M) exceed its short term liabilities ($69.1M).
Long Term Liabilities: MRUS's short term assets ($368.8M) exceed its long term liabilities ($30.1M).
Debt to Equity History and Analysis
Debt Level: MRUS is debt free.
Reducing Debt: MRUS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRUS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MRUS has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 22.8% each year.